Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise.
AffiliationMRC Cancer Trials Office, Cambridge, UK.
MetadataShow full item record
AbstractThe assessment of symptom palliation is an essential component of many treatment comparisons in clinical trials, yet an extensive literature search revealed no consensus as to its precise definition, which could embrace relief of symptoms, time to their onset, duration, degree, as well as symptom control and prevention. In an attempt to assess the importance of these aspects and to compare different methods of analysis, we used one symptom (cough) from a patient self-assessment questionnaire (the Rotterdam Symptom Checklist) in a large (>300 patient) multicentre randomized clinical trial (conducted by the Medical Research Council Lung Cancer Working Party) of palliative chemotherapy in small-cell lung cancer. The regimens compared were a two-drug regimen (2D) and a four-drug regimen (4D). No differences were seen between the regimens in time of onset of palliation or its duration. The degree of palliation was strongly related to the initial severity: 90% of the patients with moderate or severe cough at baseline reported improvement, compared with only 53% of those with mild cough. Analyses using different landmark time points gave conflicting results: the 4D regimen was superior at 1 month and at 3 months, whereas at 2 months the 2D regimen appeared superior. When improvement at any time up to 3 months was considered, the 4D regimen showed a significant benefit (4D 79%, 2D 60%, P = 0.02). These findings emphasize the need for caution in interpreting results, and the importance of working towards a standard definition of symptom palliation. The current lack of specified criteria makes analysis and interpretation of trial results difficult, and comparison across trials impossible. A standard definition of palliation for use in the analysis of clinical trials data is proposed, which takes into account aspects of onset, duration and degree of palliation, and symptom improvement, control and prevention.
CitationDefining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. 1999, 79 (3-4):538-44 Br. J. Cancer
JournalBritish Journal of Cancer
- Analysis of messy longitudinal data from a randomized clinical trial. MRC Lung Cancer Working Party.
- Authors: Qian W, Parmar MK, Sambrook RJ, Fayers PM, Girling DJ, Stephens RJ
- Issue date: 2000 Oct 15
- Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.
- Authors: Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W, Villa E, Verusio C, Cetto GL, Santo A, De Pangher V, Artioli F, Cacciani GC, Parodi G, Soresi F, Ghi MG, Morabito A, Biason R, Giusto M, Mosconi P, Chiarion Sileni V, GSTVP (Gruppo di Studio Tumori Polmonari del Veneto).
- Issue date: 2004 Jan
- Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings?
- Authors: Stephens RJ, Hopwood P, Girling DJ, Machin D
- Issue date: 1997 Apr
- Best supportive care in non-small cell lung cancer: is there a role for radiotherapy and chemotherapy?
- Authors: Numico G, Russi E, Merlano M
- Issue date: 2001 Jun
- Endobronchial brachytherapy for symptom palliation in non-small cell lung cancer--analysis of symptom response, endoscopic improvement and quality of life.
- Authors: Mallick I, Sharma SC, Behera D
- Issue date: 2007 Mar